An interventional study of Actamax™Adhesion Barrier in Uterine Fibroid, sponsored by Actamax Surgical Materials LLC. Status unknown. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2018-03-01.
Sponsored by Actamax Surgical Materials LLC · Not applicable, Interventional, and Treatment
Women undergoing laparoscopic abdominopelvic surgery with a planned, second look laparoscopy within 8-12 (+4) weeks will be enrolled. All subjects must undergo myomectomy with/without treatment of co-existing pathology e.g. (+/-) adhesions and/or (+/-) endometriosis, and/or (+/-) adenomyosis, and/or (+/-) ovarian cyst(s). The value of the second look laparoscopy (SLL) must be confirmed by the investigator to be of clinical benefit to the subject. The subject must be desirous of future fertility and willing to undergo the SLL to assess whether pathology (e.g. adnexal adhesions or endometriosis) exists which could be treated with a goal of improving their likelihood of conceiving and progressing to full term.
496 studies on the registry are indexed under Leiomyoma; 79 are open to participants now.
This study's planned enrollment of 152 is above the median of 62 across 350 interventional studies indexed under Leiomyoma.
Browse Leiomyoma studies →Actamax Surgical Materials LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Preoperative Inclusion Criteria:
Intraoperative Inclusion Criteria:
And
Preoperative Exclusion Criteria:
Intraoperative Exclusion Criteria:
Undergo a diagnostic hysteroscopy or polypectomy or therapeutic hysteroscopy which includes any of the following:
Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
Device: Actamax™Adhesion Barrier
Myomectomy will be performed with no adhesion barrier application.
Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
Adhesion Free at Sites of Surgery at SLL
The primary efficacy outcome measure will be being adhesion free at sites of surgery throughout the whole abdominopelvic cavity at SLL.
Time frame: 8-12 weeks postoperatively but out to 16 weeks where circumstances require (vacations, etc.)
No study locations are listed for this record.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Actamax Surgical Materials LLC